News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Proteonomix, Inc. (PROT) Announces Agreement With the University of Medicine and Dentistry of New Jersey to Conduct a Phase 1 Trial With UMK-121 in End-Stage Liver Disease


9/14/2012 9:00:48 AM

PARAMUS, N.J.--(BUSINESS WIRE)--Proteonomix, Inc. (OTC/BB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced it has entered into an agreement with Piscataway, N.J.-based University of Medicine and Dentistry of New Jersey (UMDNJ) to conducted a Phase 1 clinical trial with its proprietary, patent-pending mobilization technology UMK-121 in patients with end-stage liver disease (ESLD). The Company also announced that Chief Executive Officer Michael Cohen made a presentation at the National Investment Banking Association’s (NIBA) 123rd Investment Conference yesterday at the New York Marriott Downtown in New York City.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES